Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravital Microscopy in Gyn Cancers
NCT03297489Phase 1Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Nov 2017
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fluorescein sodium 10% injection in ovarian cancer, primary peritoneal carcinoma (PPC) and fallopian tube carcinoma (PFTC), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoints: Fluorescein within the tumor vessels up to 2 years, Identification of tumor vessels up to 2 years and 2 more. Started Nov 2017; status: completed.
02
Drugs
fluorescein sodium 10% injection
03
Conditions
ovarian cancerprimary peritoneal carcinoma (PPC)fallopian tube carcinoma (PFTC)
Beyond the preview
Go deeper on NCT03297489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03297489.